Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-8291 · 1 trial · 1 indication
Participants completed a pain intensity questionnaire, the Numerical Rating Scale (NRS), in the morning prior to taking study treatment at Baseline (Day 1) in each treatment period, and then daily up to Day 28 in each treatment period. The NRS assesses the intensity of Post-herpetic Neuralgia (PHN) pain during the preceding 24-hour period on an 11-point numeric rating scale (range: 0=no pain to 10=pain as bad as you can imagine). The mean score in pain intensity of Week 4 (Days 22 to 28) minus the mean score at Baseline is presented, with a negative change representing improvement (or reduction) in pain intensity. In comparison to placebo, a reduction (difference in the change from Baseline) of 1 on the 11-point NRS is expected.
| Arm | Type | Description |
|---|---|---|
| MK-8291 → Placebo | EXPERIMENTAL | In Treatment Period 1, participants were orally administered 10 mg MK-8291 once daily on Days 1 and 2, twice daily on Days 3 to 27, and once daily on Day 28 of the period. After Treatment Period 1, participants were to undergo a minimum of a 7-day Washout Period, which was followed by Treatment Period 2. In Treatment Period 2, participants were orally administered Placebo once daily on Days 1 and 2, twice daily on Days 3 to 27, and once daily on Day 28 of the period. (Total duration of treatment: up to approximately 63 days) |
| Placebo → MK-8291 | EXPERIMENTAL | In Treatment Period 1, participants were orally administered Placebo once daily on Days 1 and 2, twice daily on Days 3 to 27, and once daily on Day 28 of the period. After Treatment Period 1, participants were to undergo a minimum of a 7-day Washout Period, which was followed by Treatment Period 2. In Treatment Period 2, participants were orally administered 10 mg MK-8291 once daily on Days 1 and 2, twice daily on Days 3 to 27, and once daily on Day 28 of the period. (Total duration of treatment: up to approximately 63 days) |
| Name | Type | Description |
|---|---|---|
| MK-8291 | DRUG | MK-8291 oral tablets |
| Placebo | DRUG | Placebo oral tablets |
Inclusion Criteria: * non-pregnant female (and/or partner) agrees to use two acceptable methods of birth control throughout the trial until 2 weeks after the last dose of treatment * female is postmenopausal or surgically sterile * has a clinical diagnosis of PHN with allodynia for at least 3 month...
MK-8291 is an investigational small molecule being developed for the treatment of postherpetic neuralgia, a type of nerve pain that can occur after a shingles infection. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
MK-8291 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The drug is in Phase 1 clinical development for postherpetic neuralgia.
MK-8291 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. One Phase 1 clinical trial for the drug has been completed.
MK-8291 has one completed clinical trial, identified as NCT02336555. This Phase 1 study, titled "The Efficacy of MK-8291 in Participants With Post-herpetic Neuralgia (PHN) With Allodynia (MK-8291-012)," enrolled 35 participants with postherpetic neuralgia.
MK-8291 is the primary name for this investigational drug. No alternative names have been reported for this compound in the available clinical trial information.